RNV-1002 for CAVD Hit · Lead Compound stage selected as the national new drug development project by KDDF
RNV-1003 selected as AI Vouch Support Program for identification of potential therapeutic Hit Compounds in Aortic Stenosis
RNV-1001 selected as the national new drug development project by KDDF*
* KDDF (The Korea Drug Development Fund) is a government funded organization to accelerate innovation activities in Korean pharmaceutical R&D communities. KDDF supports the investment and development of promising drugs.
Initiate Phase 2/3 in the US
Series B Investment($19M)
IND approval for Phase Ⅱ/Ⅲ in US
Company name changed to REDNVIA
US FDA Pre-IND submission
Selected for Korean Ministry of SMEs Startup' 'K-Unicorn' program
US branch established
Research cooperation contract with US Mayo Clinic
Series A Investment ($6.7M)
Phase Ⅱ initiated in Korea
IND approval for Phase Ⅱ in Korea
Patent Transfer Agreements(L/I)
Dong-A ST(composition of matter) : DPP-4i 'Evogliptin'
Seoul Asan Hospital & Ulsan University : Use of 12 DPP-4i for CAVD
Company founded
REDNVIA Co., Ltd.
11F, 88, Olympic-ro 43-gil, Songpa-gu, Seoul,
[05505] Republic of Korea
Tel:+82-2-2039-1217 Fax: +82-70-8280-1218
For Investor relations: rednvia_contact@rednvia.com
Copyright © REDNVIA Co., Ltd. All right reserved.
